Skip to main content
Fig. 7 | Journal for ImmunoTherapy of Cancer

Fig. 7

From: Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors

Fig. 7

Boosting T cell function does not prevent recurrence after erlotinib treatment. (a) Experimental design and (b) survival curves of the erlotinib and immunotherapy combination study. CCSP-rtTA; TetO-EGFRL858R mice were treated with erlotinib alone or in combination with immunomodulatory agents as in arms 1–4 for 4 weeks after which erlotinib was halted and immunotherapy continued until mice were moribund, (n = 5–10 mice per group)

Back to article page